JP2013532959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532959A5 JP2013532959A5 JP2013510339A JP2013510339A JP2013532959A5 JP 2013532959 A5 JP2013532959 A5 JP 2013532959A5 JP 2013510339 A JP2013510339 A JP 2013510339A JP 2013510339 A JP2013510339 A JP 2013510339A JP 2013532959 A5 JP2013532959 A5 JP 2013532959A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- seq
- amino acid
- acid sequence
- polypeptide chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000024070 binding proteins Human genes 0.000 claims 35
- 108091007650 binding proteins Proteins 0.000 claims 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- -1 antibiotic Substances 0.000 claims 9
- 229940079593 drugs Drugs 0.000 claims 8
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 6
- 229940121369 angiogenesis inhibitors Drugs 0.000 claims 6
- 239000002254 cytotoxic agent Substances 0.000 claims 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims 5
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 4
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 4
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 4
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 4
- 231100000765 Toxin Toxicity 0.000 claims 4
- 239000002168 alkylating agent Substances 0.000 claims 4
- 230000003042 antagnostic Effects 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000000340 anti-metabolite Effects 0.000 claims 4
- 239000002256 antimetabolite Substances 0.000 claims 4
- 230000001640 apoptogenic Effects 0.000 claims 4
- 230000003115 biocidal Effects 0.000 claims 4
- 239000002872 contrast media Substances 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000000394 mitotic Effects 0.000 claims 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims 4
- 239000003053 toxin Substances 0.000 claims 4
- 108020003112 toxins Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 229940070021 ANABOLIC STEROIDS Drugs 0.000 claims 2
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 claims 2
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims 2
- 229960001334 Corticosteroids Drugs 0.000 claims 2
- 229940119017 Cyclosporine Drugs 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 229940088597 Hormone Drugs 0.000 claims 2
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 claims 2
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims 2
- 102000018358 Immunoglobulins Human genes 0.000 claims 2
- 108060003951 Immunoglobulins Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003263 anabolic agent Substances 0.000 claims 2
- 230000003444 anaesthetic Effects 0.000 claims 2
- 230000000202 analgesic Effects 0.000 claims 2
- 230000000844 anti-bacterial Effects 0.000 claims 2
- 230000003092 anti-cytokine Effects 0.000 claims 2
- 230000001430 anti-depressive Effects 0.000 claims 2
- 230000002682 anti-psoriatic Effects 0.000 claims 2
- 230000000561 anti-psychotic Effects 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 239000003435 antirheumatic agent Substances 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 230000000139 costimulatory Effects 0.000 claims 2
- 230000001809 detectable Effects 0.000 claims 2
- 229960005139 epinephrine Drugs 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 230000001861 immunosuppresant Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 239000003589 local anesthetic agent Substances 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 239000003158 myorelaxant agent Substances 0.000 claims 2
- 230000003533 narcotic Effects 0.000 claims 2
- 239000000842 neuromuscular blocking agent Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 239000012217 radiopharmaceutical Substances 0.000 claims 2
- 230000002799 radiopharmaceutical Effects 0.000 claims 2
- 230000001624 sedative Effects 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
Claims (30)
- 第１および第２のポリペプチド鎖を含む結合タンパク質であって、
第１のポリペプチド鎖が、第１のＶＤ１−（Ｘ１）ｎ−ＶＤ２−Ｃ−（Ｘ２）ｎ［式中、
ＶＤ１は、第１の重鎖可変ドメインであり；
ＶＤ２は、第２の重鎖可変ドメインであり；
Ｃは、重鎖定常ドメインであり；
Ｘ１は、ＣＨ１ではないという条件で、リンカーであり；
Ｘ２は、Ｆｃ領域であり；および
ｎは独立に、０または１である］
を含み、
第２のポリペプチド鎖が、第２のＶＤ１−（Ｘ１）ｎ−ＶＤ２−Ｃ−（Ｘ２）ｎ［式中、
ＶＤ１は、第１の軽鎖可変ドメインであり；
ＶＤ２は、第２の軽鎖可変ドメインであり；
Ｃは、軽鎖定常ドメインであり；
Ｘ１は、ＣＨ１ではないという条件で、リンカーであり；
Ｘ２は、Ｆｃ領域を含まず；および
ｎは独立に、０または１である］
を含み、
前記の第１のポリペプチド鎖中、ＶＤ１は、配列番号２０４のアミノ酸配列を含み；ＶＤ２は、配列番号２１３のアミノ酸配列を含み；
前記の第２のポリペプチド鎖中、ＶＤ１は、配列番号２３８のアミノ酸配列を含み；ＶＤ２は、配列番号２１６のアミノ酸配列を含み；
結合タンパク質が、ヒトＩＬ−１βおよびヒトＩＬ−１αと結合する、前記結合タンパク質。 - 第１および第２のポリペプチド鎖を含む結合タンパク質であって、
第１のポリペプチド鎖が、第１のＶＤ１−（Ｘ１）ｎ−ＶＤ２−Ｃ−（Ｘ２）ｎ［式中、
ＶＤ１は、第１の重鎖可変ドメインであり；
ＶＤ２は、第２の重鎖可変ドメインであり；
Ｃは、重鎖定常ドメインであり；
Ｘ１は、ＣＨ１ではないという条件で、リンカーであり；
Ｘ２は、Ｆｃ領域であり；および
ｎは独立に、０または１である］
を含み、
第２のポリペプチド鎖が、第２のＶＤ１−（Ｘ１）ｎ−ＶＤ２−Ｃ−（Ｘ２）ｎ［式中、
ＶＤ１は、第１の軽鎖可変ドメインであり；
ＶＤ２は、第２の軽鎖可変ドメインであり；
Ｃは、軽鎖定常ドメインであり；
Ｘ１は、ＣＨ１ではないという条件で、リンカーであり；
Ｘ２は、Ｆｃ領域を含まず；および
ｎは独立に、０または１である］
を含み、
前記の第１のポリペプチド鎖中、ＶＤ１は、配列番号２１３のアミノ酸配列を含み；ＶＤ２は、配列番号２０４のアミノ酸配列を含み；
前記の第２のポリペプチド鎖中、ＶＤ１は、配列番号２１６のアミノ酸配列を含み；ＶＤ２は、配列番号２３８のアミノ酸配列を含み；
結合タンパク質が、ヒトＩＬ−１βおよびヒトＩＬ−１αと結合する、前記結合タンパク質。 - 前記の第１のポリペプチド鎖が、配列番号２１２のアミノ酸配列を含む、請求項１に記載の結合タンパク質。
- 前記の第２のポリペプチド鎖が、配列番号２１５のアミノ酸配列を含む、請求項１に記載の結合タンパク質。
- 前記の第１のポリペプチド鎖が、配列番号２１９のアミノ酸配列を含む、請求項２に記載の結合タンパク質。
- 前記の第２のポリペプチド鎖が、配列番号２２０のアミノ酸配列を含む、請求項２に記載の結合タンパク質。
- 前記の第１のポリペプチド鎖が配列番号２１２のアミノ酸配列を含み、および前記の第２のポリペプチド鎖が配列番号２１５のアミノ酸配列を含む、請求項１に記載の結合タンパク質。
- 前記の第１のポリペプチド鎖が配列番号２１９のアミノ酸配列を含み、および前記の第２のポリペプチド鎖が配列番号２２０のアミノ酸配列を含む、請求項２に記載の結合タンパク質。
- ２つの第１のポリペプチド鎖および２つの第２のポリペプチド鎖を含む、請求項１に記載の結合タンパク質。
- Ｘ１またはＸ２が、配列番号２６−５７、２２３、２２４および２２５からなる群から選択されるアミノ酸配列である、請求項１に記載の結合タンパク質。
- Ｆｃ領域が、変異体配列Ｆｃ領域である、請求項１に記載の結合タンパク質。
- 請求項１に記載の結合タンパク質を含み、さらに免疫接着分子、造影剤、治療薬および細胞傷害性薬剤からなる群から選択される薬剤を含む、結合タンパク質コンジュゲート。
- 前記薬剤が、抗代謝生成物、アルキル化剤、抗生物質、増殖因子、サイトカイン、血管新生抑制薬、有糸分裂阻害剤、アントラサイクリン、毒素およびアポトーシス薬からなる群から選択される治療薬または細胞傷害性薬剤である、請求項１２に記載の結合タンパク質コンジュゲート。
- 請求項１に記載の結合タンパク質と、医薬上許容される担体を含む医薬組成物。
- 少なくとも１種のさらなる薬剤を含む、請求項１４に記載の医薬組成物。
- さらなる薬剤が、治療薬、造影剤、細胞傷害性薬剤、血管新生抑制薬、キナーゼ阻害剤、共刺激分子遮断薬、接着分子遮断薬、抗サイトカイン抗体またはその機能的断片、メトトレキサート、シクロスポリン、ラパマイシン、ＦＫ５０６、検出可能な標識またはリポーター、ＴＮＦアンタゴニスト、抗リウマチ薬、筋弛緩薬、麻薬、非ステロイド抗炎症剤（ＮＳＡＩＤ）、鎮痛薬、麻酔薬、鎮静薬、局所麻酔薬、神経筋遮断薬、抗菌薬、抗乾癬薬、コルチコステロイド、アナボリックステロイド、エリスロポエチン、免疫処置、免疫グロブリン、免疫抑制剤、成長ホルモン、ホルモン置換薬、放射性医薬品、抗鬱薬、抗精神病薬、刺激薬、喘息薬物、βアゴニスト、吸入ステロイド、エピネフリンまたはその類似体、サイトカインおよびサイトカインアンタゴニストからなる群から選択される、請求項１５に記載の医薬組成物。
- 請求項１２に記載の結合タンパク質コンジュゲートと、医薬上許容される担体を含む医薬組成物。
- 結合タンパク質コンジュゲートが、抗代謝生成物、アルキル化剤、抗生物質、増殖因子、サイトカイン、血管新生抑制薬、有糸分裂阻害剤、アントラサイクリン、毒素およびアポトーシス薬からなる群から選択される治療薬または細胞傷害性薬剤を含む、請求項１７に記載の医薬組成物。
- ２つの第１のポリペプチド鎖および２つの第２のポリペプチド鎖を含む、請求項２に記載の結合タンパク質。
- Ｘ１またはＸ２が、配列番号２６−５７、２２３、２２４および２２５からなる群から選択されるアミノ酸配列である、請求項２に記載の結合タンパク質。
- Ｆｃ領域が、変異体配列Ｆｃ領域である、請求項２に記載の結合タンパク質。
- 請求項２に記載の結合タンパク質を含み、さらに免疫接着分子、造影剤、治療薬および細胞傷害性薬剤からなる群から選択される薬剤を含む、結合タンパク質コンジュゲート。
- 前記薬剤が、抗代謝生成物、アルキル化剤、抗生物質、増殖因子、サイトカイン、血管新生抑制薬、有糸分裂阻害剤、アントラサイクリン、毒素およびアポトーシス薬からなる群から選択される治療薬または細胞傷害性薬剤である、請求項２２に記載の結合タンパク質コンジュゲート。
- 請求項２に記載の結合タンパク質と、医薬上許容される担体を含む医薬組成物。
- 少なくとも１種のさらなる薬剤を含む、請求項２４に記載の医薬組成物。
- さらなる薬剤が、治療薬、造影剤、細胞傷害性薬剤、血管新生抑制薬、キナーゼ阻害剤、共刺激分子遮断薬、接着分子遮断薬、抗サイトカイン抗体またはその機能的断片、メトトレキサート、シクロスポリン、ラパマイシン、ＦＫ５０６、検出可能な標識またはリポーター、ＴＮＦアンタゴニスト、抗リウマチ薬、筋弛緩薬、麻薬、非ステロイド抗炎症剤（ＮＳＡＩＤ）、鎮痛薬、麻酔薬、鎮静薬、局所麻酔薬、神経筋遮断薬、抗菌薬、抗乾癬薬、コルチコステロイド、アナボリックステロイド、エリスロポエチン、免疫処置、免疫グロブリン、免疫抑制剤、成長ホルモン、ホルモン置換薬、放射性医薬品、抗鬱薬、抗精神病薬、刺激薬、喘息薬物、βアゴニスト、吸入ステロイド、エピネフリンまたはその類似体、サイトカインおよびサイトカインアンタゴニストからなる群から選択される、請求項２５に記載の医薬組成物。
- 請求項２２に記載の結合タンパク質コンジュゲートと、医薬上許容される担体を含む医薬組成物。
- 前記薬剤が、抗代謝生成物、アルキル化剤、抗生物質、増殖因子、サイトカイン、血管新生抑制薬、有糸分裂阻害剤、アントラサイクリン、毒素およびアポトーシス薬からなる群から選択される治療薬または細胞傷害性薬剤である、請求項２７に記載の医薬組成物。
- 第１および第２のポリペプチド鎖を含む結合タンパク質であって、
第１のポリペプチド鎖が、第１のＶＤ１−（Ｘ１）ｎ−ＶＤ２−Ｃ−（Ｘ２）ｎ［式中、
ＶＤ１は、第１の重鎖可変ドメインであり；
ＶＤ２は、第２の重鎖可変ドメインであり；
Ｃは、重鎖定常ドメインであり；
Ｘ１は、ＣＨ１ではないという条件で、リンカーであり；
Ｘ２は、Ｆｃ領域であり；および
ｎは独立に、０または１である］
を含み、
第２のポリペプチド鎖が、第２のＶＤ１−（Ｘ１）ｎ−ＶＤ２−Ｃ−（Ｘ２）ｎ［式中、
ＶＤ１は、第１の軽鎖可変ドメインであり；
ＶＤ２は、第２の軽鎖可変ドメインであり；
Ｃは、軽鎖定常ドメインであり；
Ｘ１は、ＣＨ１ではないという条件で、リンカーであり；
Ｘ２は、Ｆｃ領域を含まず；および
ｎは独立に、０または１である］
を含み、
前記の第１のポリペプチド鎖中、ＶＤ１は、配列番号２０４のアミノ酸配列を含み；ＶＤ２は、配列番号２１３のアミノ酸配列を含み；
前記の第２のポリペプチド鎖中、ＶＤ１は、配列番号２３８のアミノ酸配列を含み；ＶＤ２は、配列番号２１６のアミノ酸配列を含み；
前記の第１のポリペプチド鎖が配列番号２１２のアミノ酸配列を含み、および前記の第２のポリペプチド鎖が配列番号２１５のアミノ酸配列を含み、
結合タンパク質が、ヒトＩＬ−１βおよびヒトＩＬ−１αと結合する、前記結合タンパク質。 - 第１および第２のポリペプチド鎖を含む結合タンパク質であって、
第１のポリペプチド鎖が、第１のＶＤ１−（Ｘ１）ｎ−ＶＤ２−Ｃ−（Ｘ２）ｎ［式中、
ＶＤ１は、第１の重鎖可変ドメインであり；
ＶＤ２は、第２の重鎖可変ドメインであり；
Ｃは、重鎖定常ドメインであり；
Ｘ１は、ＣＨ１ではないという条件で、リンカーであり；
Ｘ２は、Ｆｃ領域であり；および
ｎは独立に、０または１である］
を含み、
第２のポリペプチド鎖が、第２のＶＤ１−（Ｘ１）ｎ−ＶＤ２−Ｃ−（Ｘ２）ｎ［式中、
ＶＤ１は、第１の軽鎖可変ドメインであり；
ＶＤ２は、第２の軽鎖可変ドメインであり；
Ｃは、軽鎖定常ドメインであり；
Ｘ１は、ＣＨ１ではないという条件で、リンカーであり；
Ｘ２は、Ｆｃ領域を含まず；および
ｎは独立に、０または１である］
を含み、
前記の第１のポリペプチド鎖中、ＶＤ１は、配列番号２１３のアミノ酸配列を含み；ＶＤ２は、配列番号２０４のアミノ酸配列を含み；
前記の第２のポリペプチド鎖中、ＶＤ１は、配列番号２１６のアミノ酸配列を含み；ＶＤ２は、配列番号２３８のアミノ酸配列を含み；
前記の第１のポリペプチド鎖が配列番号２１９のアミノ酸配列を含み、および前記の第２のポリペプチド鎖が配列番号２２０のアミノ酸配列を含み；
結合タンパク質が、ヒトＩＬ−１βおよびヒトＩＬ−１αと結合する、前記結合タンパク質。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33491710P | 2010-05-14 | 2010-05-14 | |
| US61/334,917 | 2010-05-14 | ||
| US201061425701P | 2010-12-21 | 2010-12-21 | |
| US61/425,701 | 2010-12-21 | ||
| PCT/US2011/036444 WO2011143562A2 (en) | 2010-05-14 | 2011-05-13 | Il-1 binding proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014085634A Division JP5881766B2 (ja) | 2010-05-14 | 2014-04-17 | Ｉｌ−１結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532959A JP2013532959A (ja) | 2013-08-22 |
| JP2013532959A5 true JP2013532959A5 (ja) | 2014-06-05 |
| JP5684372B2 JP5684372B2 (ja) | 2015-03-11 |
Family
ID=44911961
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510339A Active JP5684372B2 (ja) | 2010-05-14 | 2011-05-13 | Ｉｌ−１結合タンパク質 |
| JP2014085634A Active JP5881766B2 (ja) | 2010-05-14 | 2014-04-17 | Ｉｌ−１結合タンパク質 |
| JP2016016871A Active JP6189980B2 (ja) | 2010-05-14 | 2016-02-01 | Ｉｌ−１結合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014085634A Active JP5881766B2 (ja) | 2010-05-14 | 2014-04-17 | Ｉｌ−１結合タンパク質 |
| JP2016016871A Active JP6189980B2 (ja) | 2010-05-14 | 2016-02-01 | Ｉｌ−１結合タンパク質 |
Country Status (36)
| Country | Link |
|---|---|
| US (10) | US8841417B2 (ja) |
| EP (1) | EP2571532B1 (ja) |
| JP (3) | JP5684372B2 (ja) |
| KR (3) | KR101539684B1 (ja) |
| CN (2) | CN103025758B (ja) |
| AR (1) | AR081246A1 (ja) |
| AU (1) | AU2011252883B2 (ja) |
| BR (2) | BR122014011544A2 (ja) |
| CA (1) | CA2799046C (ja) |
| CL (2) | CL2012003187A1 (ja) |
| CO (1) | CO6640269A2 (ja) |
| CR (1) | CR20120581A (ja) |
| CY (1) | CY1120434T1 (ja) |
| DK (1) | DK2571532T3 (ja) |
| DO (1) | DOP2012000288A (ja) |
| EC (1) | ECSP12012307A (ja) |
| ES (1) | ES2635594T3 (ja) |
| GT (1) | GT201200308A (ja) |
| HR (1) | HRP20171144T1 (ja) |
| HU (1) | HUE033063T2 (ja) |
| IL (1) | IL222980B (ja) |
| LT (1) | LT2571532T (ja) |
| MX (2) | MX350723B (ja) |
| MY (1) | MY161302A (ja) |
| NZ (2) | NZ604360A (ja) |
| PE (1) | PE20130205A1 (ja) |
| PH (1) | PH12016501036A1 (ja) |
| PL (1) | PL2571532T3 (ja) |
| PT (1) | PT2571532T (ja) |
| RS (1) | RS56316B1 (ja) |
| RU (1) | RU2615173C2 (ja) |
| SG (2) | SG185502A1 (ja) |
| SI (1) | SI2571532T1 (ja) |
| TW (3) | TWI615405B (ja) |
| UY (1) | UY33386A (ja) |
| WO (1) | WO2011143562A2 (ja) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2664323B1 (en) | 2007-04-16 | 2020-07-29 | Corium, Inc. | Solvent-cast microneedle arrays containing active |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| RU2011135768A (ru) * | 2009-01-29 | 2013-03-10 | Эбботт Лэборетриз | Белки, связывающие il-1 |
| US20120178100A1 (en) * | 2009-07-28 | 2012-07-12 | Centocor Ortho Biotech Inc. | Serum Markers Predicting Clinical Response to Anti-TNF Alpha Antibodies in Patients with Psoriatic Arthritis |
| MX2012002605A (es) | 2009-08-29 | 2012-04-02 | Abbott Lab | Proteinas terapeutico de union a dll4. |
| AR078650A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Anticuerpo de union a il-1 beta |
| BR112012021941A2 (pt) | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
| ES2719595T3 (es) | 2010-05-04 | 2019-07-11 | Corium Int Inc | Método y dispositivo para la administración transdérmica de la hormona paratiroidea usando una matriz de microproyección |
| KR101539684B1 (ko) * | 2010-05-14 | 2015-07-27 | 애브비 인코포레이티드 | Ｉｌ－１ 결합 단백질 |
| AU2011285852B2 (en) * | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| PE20140229A1 (es) | 2010-08-26 | 2014-03-27 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CA2821976A1 (en) * | 2010-12-21 | 2012-09-13 | Abbvie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| JP5918275B2 (ja) * | 2011-02-08 | 2016-05-18 | アッヴィ・インコーポレイテッド | 変形性関節症及び疼痛の治療 |
| US20140348838A1 (en) * | 2011-11-21 | 2014-11-27 | Abbvie Inc. | Il-1 binding proteins |
| AU2012362326A1 (en) | 2011-12-30 | 2014-07-24 | Abbvie Inc. | Dual variable domain immunoglobulins against IL-13 and/or IL-17 |
| WO2013148202A1 (en) * | 2012-03-29 | 2013-10-03 | Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine | Novel compositions and methods for preventing or treating cancer metastasis |
| AR091755A1 (es) | 2012-07-12 | 2015-02-25 | Abbvie Inc | Proteinas de union a il-1 |
| CN103588878A (zh) * | 2012-08-15 | 2014-02-19 | 江苏泰康生物医药有限公司 | 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用 |
| SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| EP2914626A2 (en) * | 2012-11-01 | 2015-09-09 | Abbvie Inc. | Stable dual variable domain immunoglobulin protein formulations |
| EP2934660B1 (en) | 2012-12-21 | 2019-07-17 | Corium, Inc. | Microarray for delivery of therapeutic agent and method of making same |
| WO2014117035A1 (en) | 2013-01-24 | 2014-07-31 | Transderm, Inc. | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS |
| US9844607B2 (en) * | 2013-02-05 | 2017-12-19 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| CA2903748C (en) | 2013-03-12 | 2021-11-02 | Corium International, Inc. | Microprojection applicators |
| WO2014150285A2 (en) | 2013-03-15 | 2014-09-25 | Corium International, Inc. | Multiple impact microprojection applicators and methods of use |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| AU2014237279B2 (en) * | 2013-03-15 | 2018-11-22 | Corium Pharma Solutions, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
| CN105246458B (zh) | 2013-03-15 | 2020-09-15 | 考里安公司 | 用于治疗剂递送的微阵列及其使用方法 |
| US20160153973A1 (en) * | 2013-07-09 | 2016-06-02 | Lucas David Smith | Device and method of rapid linker mediated label-based immunoassays |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| AU2014360704A1 (en) | 2013-12-02 | 2016-05-19 | Abbvie, Inc. | Compositions and methods for treating osteoarthritis |
| RU2019118984A (ru) | 2014-01-10 | 2019-08-06 | Анаптисбайо, Инк. | Антитела, направленные против интерлейкина-33 (il-33) |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| ES2792682T3 (es) | 2014-02-10 | 2020-11-11 | Respivant Sciences Gmbh | Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos |
| PT3104853T (pt) | 2014-02-10 | 2020-01-14 | Respivant Sciences Gmbh | Tratamento com estabilizadores de mastócitos para distúrbios sistémicos |
| WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| WO2016036866A1 (en) | 2014-09-04 | 2016-03-10 | Corium International, Inc. | Microstructure array, methods of making, and methods of use |
| EP3925622A1 (en) | 2014-09-13 | 2021-12-22 | Novartis AG | Combination therapies |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| KR101676542B1 (ko) | 2014-12-30 | 2016-11-16 | 건국대학교 산학협력단 | 프로인슐린의 면역학적 용도 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| US10857093B2 (en) | 2015-06-29 | 2020-12-08 | Corium, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
| KR20180030180A (ko) * | 2015-07-16 | 2018-03-21 | 필로겐 에스.피.에이. | Il22 면역컨쥬게이트 |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| CN114191428A (zh) | 2016-03-02 | 2022-03-18 | 卫材研究发展管理有限公司 | 基于艾日布林的抗体-药物偶联物和使用方法 |
| EP3436476A4 (en) * | 2016-03-28 | 2020-04-29 | The Regents of The University of California | ANTI-RYK ANTIBODIES AND METHOD FOR USE THEREOF |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| SG10201606949QA (en) | 2016-08-19 | 2018-03-28 | Singapore Health Serv Pte Ltd | Immunosuppressive composition for use in treating immunological disorders |
| CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| CA3036230A1 (en) | 2016-09-08 | 2018-03-15 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of hypercytokinemia and viral infection |
| CN109803724A (zh) | 2016-10-07 | 2019-05-24 | 瑞思皮万特科学有限责任公司 | 用于治疗肺纤维化的色甘酸组合物 |
| WO2018075574A1 (en) | 2016-10-18 | 2018-04-26 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of chronic inflammatory conditions |
| EP3312608B1 (en) * | 2016-10-24 | 2019-10-02 | Akribes Biomedical GmbH | Methods for identifying a non-healing skin wound and for monitoring the healing of a skin wound |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| CA3049402A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| US20210031012A1 (en) * | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| CN109187943B (zh) * | 2018-08-24 | 2021-07-30 | 四川新健康成生物股份有限公司 | 一种抗干扰试剂杯以及试剂杯内抗干扰涂层的制备方法 |
| WO2020172622A1 (en) * | 2019-02-21 | 2020-08-27 | Washington University | Methods of detecting septic arthritis, transient synovitis and osteomyelitis |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2020223608A1 (en) * | 2019-05-02 | 2020-11-05 | Thiolab, Llc, | Inhibition of il-1 and il-6 inflammation |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| KR102267495B1 (ko) * | 2019-08-07 | 2021-06-22 | 연세대학교 산학협력단 | 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도 |
| CN110680905A (zh) * | 2019-10-24 | 2020-01-14 | 内蒙古医科大学第二附属医院 | Tslp在制备治疗腰椎间盘突出药物中的应用 |
| CN111057733A (zh) * | 2020-01-31 | 2020-04-24 | 桂林理工大学 | 一种从生物质石灰废渣中提取胶原蛋白的方法 |
| IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Antibodies against interleukin-33 and uses thereof |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN111679073B (zh) * | 2020-06-17 | 2021-10-19 | 南京市妇幼保健院 | Klk13在制备诊断宫颈腺癌检测试剂盒上的应用 |
Family Cites Families (177)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| EP1186660A3 (fr) | 1985-03-30 | 2002-03-20 | KAUFFMAN, Stuart A. | Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ES2063735T3 (es) | 1986-10-22 | 1995-01-16 | Abbott Lab | Sales de acridinio quimioluminiscentes. |
| US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
| US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
| ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5241070A (en) | 1988-09-26 | 1993-08-31 | Ciba Corning Diagnostics Corp. | Nucleophilic polysubstituted aryl acridinium esters and uses thereof |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| SE462454B (sv) | 1988-11-10 | 1990-06-25 | Pharmacia Ab | Maetyta foer anvaendning i biosensorer |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| EP0478627A4 (en) | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| CA2048302A1 (en) | 1990-08-15 | 1992-02-16 | Victoria P. Meucci | Solubilization reagent for biological test samples |
| US5135875A (en) | 1990-08-15 | 1992-08-04 | Abbott Laboratories | Protein precipitation reagent |
| ATE174598T1 (de) | 1990-08-24 | 1999-01-15 | Ixsys Inc | Verfahren zur herstellung von oligonukleotiden mit regellosen codonen |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| EP0563296B1 (en) | 1990-12-20 | 1999-03-17 | Ixsys, Inc. | Optimization of binding proteins |
| CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
| SK281142B6 (sk) | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
| JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
| AU666852B2 (en) | 1991-05-01 | 1996-02-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
| EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
| US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69328622T2 (de) | 1992-03-30 | 2001-02-08 | Abbott Lab | Reagenzien und verfahren zum nachweis und zur quantifizierung von thyroxin in flüssigen proben |
| US5352803A (en) | 1992-03-30 | 1994-10-04 | Abbott Laboratories | 5(6)-methyl substituted fluorescein derivatives |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| WO1994018219A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| GB9314098D0 (en) | 1993-07-08 | 1993-08-18 | Unilever Plc | Apparatus and methods for producing packets |
| WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| US5959085A (en) | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| CA2195557C (en) | 1994-08-12 | 2006-10-17 | Shui-On Leung | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| WO1996020698A2 (en) | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Surface-modified nanoparticles and method of making and using same |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| JPH11503914A (ja) | 1995-04-21 | 1999-04-06 | セル ジェネシス，インコーポレイテッド | 大ゲノムｄｎａ欠失の生成 |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| CA2230494A1 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
| US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| AU2063197A (en) | 1996-03-04 | 1997-09-22 | Massachusetts Institute Of Technology | Materials and methods for enhancing cellular internalization |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| EP0971946B1 (en) | 1997-01-21 | 2006-07-05 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
| EP1007967A2 (en) | 1997-08-04 | 2000-06-14 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク． | 治療薬としてのｃｄ１４７結合分子 |
| IL138668A0 (en) | 1998-04-03 | 2001-10-31 | Phylos Inc | Addressable protein arrays |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| AU4025300A (en) | 1999-03-24 | 2000-10-09 | Packard Bioscience Company | Continuous porous matrix arrays |
| TR200102715T2 (tr) | 1999-03-25 | 2002-09-23 | Knoll Gmbh | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| UA77157C2 (en) | 2000-02-25 | 2006-11-15 | Polypeptide anti-egfrviii scfvs with improved cytotoxicity and output, molecule of nucleic acid, that codes the indicated polypeptide, and method of cell destructure with using of this polypeptide | |
| NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
| AU5943201A (en) | 2000-05-03 | 2001-11-12 | Amgen Inc | Modified peptides as therapeutic agents |
| AU2001258567A1 (en) | 2000-05-19 | 2001-11-26 | Scancell Limited | Humanised antibodies to the epidermal growth factor receptor |
| AU7684201A (en) | 2000-06-28 | 2002-01-08 | Glycofi Inc | Methods for producing modified glycoproteins |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| DE60137421D1 (de) | 2000-06-29 | 2009-03-05 | Abbott Lab | Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung |
| IL156618A0 (en) | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
| JP2002270125A (ja) | 2001-03-07 | 2002-09-20 | Hitachi Ltd | 高電圧電気機器 |
| CA2450285C (en) | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| EP1432444A4 (en) | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
| WO2003029456A1 (en) | 2001-10-01 | 2003-04-10 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
| AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
| WO2003039486A2 (en) | 2001-11-09 | 2003-05-15 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
| DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
| US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
| NZ556507A (en) * | 2002-06-03 | 2010-03-26 | Genentech Inc | Synthetic antibody phage libraries |
| CA2872136C (en) | 2002-07-18 | 2017-06-20 | Merus B.V. | Recombinant production of mixtures of antibodies |
| US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
| BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JP4464395B2 (ja) | 2003-03-05 | 2010-05-19 | ヘイローザイム インコーポレイテッド | 可溶性ヒアルロニダーゼ糖タンパク質（ｓＨＡＳＥＧＰ）、その調製プロセス、使用およびそれを含む薬学的組成物 |
| EP1660534A2 (en) | 2003-08-22 | 2006-05-31 | MedImmune, Inc. | Humanization of antibodies |
| US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
| US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
| US7968684B2 (en) * | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| WO2005100584A2 (en) | 2004-04-15 | 2005-10-27 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| WO2005111082A1 (en) | 2004-04-30 | 2005-11-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-tfr antibody. |
| DOP2006000093A (es) | 2005-04-25 | 2007-01-31 | Pfizer | Anticuerpos contra miostatina |
| TW201444869A (zh) * | 2005-06-30 | 2014-12-01 | Abbvie Inc | Ｉｌ-１２／ｐ４０結合蛋白 |
| AU2006274698B2 (en) | 2005-08-02 | 2011-06-09 | Xbiotech, Inc. | Diagnosis, treatment, and prevention of vascular disorders using IL-1a autoantibodies |
| SG2014010029A (en) * | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PL2848258T3 (pl) * | 2005-10-26 | 2018-06-29 | Novartis Ag | Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta |
| WO2007077042A1 (en) | 2006-01-06 | 2007-07-12 | Topotarget Switzerland Sa | New method for the treatment of gout or pseudogout |
| GEP20125628B (en) | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| WO2007135546A2 (en) | 2006-05-22 | 2007-11-29 | Xbiotech Inc. | TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES |
| US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| JP5319549B2 (ja) | 2006-12-29 | 2013-10-16 | アボット・ラボラトリーズ | 溶液内捕捉イムノアッセイで使用する非変性細胞溶解試薬 |
| WO2008082651A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Dual-specific il-1a/ il-1b antibodies |
| US7906293B2 (en) | 2007-04-09 | 2011-03-15 | Abbott Laboratories | Acridinium phenyl esters useful in the analysis of biological |
| ES2828627T3 (es) * | 2008-04-25 | 2021-05-27 | Kyowa Kirin Co Ltd | Anticuerpo multivalente estable |
| WO2009148575A1 (en) | 2008-05-30 | 2009-12-10 | Xbiotech, Inc. | Interleukin-1 alpha abs and methods of use |
| NZ589434A (en) * | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009291536B2 (en) | 2008-09-12 | 2012-08-16 | Xbiotech Inc. | Targeting pathogenic monocytes |
| AU2009298501A1 (en) | 2008-09-30 | 2010-04-08 | Abbvie Inc. | Improved antibody libraries |
| CA2749041C (en) | 2008-12-31 | 2019-09-03 | Abbott Point Of Care Inc. | Method and device for immunoassay using obligonucleotide conjugates |
| EP2403531A4 (en) | 2009-03-05 | 2013-02-27 | Abbott Lab | IL-17 BINDING PROTEINS |
| KR101539684B1 (ko) | 2010-05-14 | 2015-07-27 | 애브비 인코포레이티드 | Ｉｌ－１ 결합 단백질 |
| AU2011285852B2 (en) * | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
-
2011
- 2011-05-13 KR KR1020147026771A patent/KR101539684B1/ko active IP Right Grant
- 2011-05-13 SG SG2012082723A patent/SG185502A1/en unknown
- 2011-05-13 NZ NZ604360A patent/NZ604360A/en unknown
- 2011-05-13 BR BR122014011544A patent/BR122014011544A2/pt not_active Application Discontinuation
- 2011-05-13 JP JP2013510339A patent/JP5684372B2/ja active Active
- 2011-05-13 NZ NZ628792A patent/NZ628792A/en unknown
- 2011-05-13 BR BR112012031071-2A patent/BR112012031071B1/pt active IP Right Grant
- 2011-05-13 UY UY0001033386A patent/UY33386A/es not_active Application Discontinuation
- 2011-05-13 LT LTEP11781350.1T patent/LT2571532T/lt unknown
- 2011-05-13 MX MX2015016696A patent/MX350723B/es unknown
- 2011-05-13 WO PCT/US2011/036444 patent/WO2011143562A2/en active Application Filing
- 2011-05-13 MY MYPI2012700928A patent/MY161302A/en unknown
- 2011-05-13 KR KR1020157008539A patent/KR101848225B1/ko active IP Right Grant
- 2011-05-13 ES ES11781350.1T patent/ES2635594T3/es active Active
- 2011-05-13 CN CN201180034631.XA patent/CN103025758B/zh active Active
- 2011-05-13 TW TW104144064A patent/TWI615405B/zh active
- 2011-05-13 EP EP11781350.1A patent/EP2571532B1/en active Active
- 2011-05-13 HU HUE11781350A patent/HUE033063T2/hu unknown
- 2011-05-13 AU AU2011252883A patent/AU2011252883B2/en active Active
- 2011-05-13 US US13/107,439 patent/US8841417B2/en active Active
- 2011-05-13 AR ARP110101662A patent/AR081246A1/es unknown
- 2011-05-13 SG SG10201509747VA patent/SG10201509747VA/en unknown
- 2011-05-13 MX MX2012013187A patent/MX2012013187A/es unknown
- 2011-05-13 SI SI201131255T patent/SI2571532T1/sl unknown
- 2011-05-13 TW TW103130032A patent/TWI522365B/zh active
- 2011-05-13 PL PL11781350T patent/PL2571532T3/pl unknown
- 2011-05-13 KR KR1020127032684A patent/KR101539683B1/ko active IP Right Grant
- 2011-05-13 PE PE2012002166A patent/PE20130205A1/es active IP Right Grant
- 2011-05-13 PT PT117813501T patent/PT2571532T/pt unknown
- 2011-05-13 CA CA2799046A patent/CA2799046C/en active Active
- 2011-05-13 RU RU2012154210A patent/RU2615173C2/ru active
- 2011-05-13 DK DK11781350.1T patent/DK2571532T3/en active
- 2011-05-13 RS RS20170759A patent/RS56316B1/sr unknown
- 2011-05-13 TW TW100116951A patent/TWI500427B/zh active
- 2011-05-13 CN CN201510187627.7A patent/CN104804089A/zh active Pending
-
2012
- 2012-11-11 IL IL222980A patent/IL222980B/en active IP Right Grant
- 2012-11-13 DO DO2012000288A patent/DOP2012000288A/es unknown
- 2012-11-13 GT GT201200308A patent/GT201200308A/es unknown
- 2012-11-14 CR CR20120581A patent/CR20120581A/es unknown
- 2012-11-14 CL CL2012003187A patent/CL2012003187A1/es unknown
- 2012-11-26 EC ECSP12012307 patent/ECSP12012307A/es unknown
- 2012-12-11 CO CO12224263A patent/CO6640269A2/es unknown
-
2013
- 2013-03-20 US US13/847,862 patent/US8664367B2/en active Active
- 2013-12-12 US US14/104,991 patent/US9303085B2/en active Active
- 2013-12-16 US US14/107,988 patent/US9447183B2/en active Active
- 2013-12-17 US US14/109,606 patent/US9441038B2/en active Active
- 2013-12-18 US US14/133,380 patent/US9409986B2/en active Active
- 2013-12-26 US US14/141,317 patent/US9447184B2/en active Active
-
2014
- 2014-04-17 JP JP2014085634A patent/JP5881766B2/ja active Active
-
2016
- 2016-02-01 JP JP2016016871A patent/JP6189980B2/ja active Active
- 2016-02-11 CL CL2016000333A patent/CL2016000333A1/es unknown
- 2016-05-16 US US15/156,261 patent/US20170058027A1/en not_active Abandoned
- 2016-06-01 PH PH12016501036A patent/PH12016501036A1/en unknown
-
2017
- 2017-07-26 HR HRP20171144TT patent/HRP20171144T1/hr unknown
- 2017-07-31 CY CY20171100816T patent/CY1120434T1/el unknown
-
2019
- 2019-02-01 US US16/265,614 patent/US20190389945A1/en not_active Abandoned
-
2022
- 2022-04-29 US US17/733,303 patent/US20230112863A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532959A5 (ja) | ||
| JP2017160203A5 (ja) | ||
| JP2014520847A5 (ja) | ||
| AR082461A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| JP2017500018A5 (ja) | ||
| JP2013520993A5 (ja) | ||
| HRP20170531T1 (hr) | Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze | |
| RU2014105288A (ru) | Способы и композиции для лечения астмы с использованием антител против il-13 | |
| HRP20131107T1 (hr) | Anti-notch1 nrr-protutijela i postupak njihove uporabe | |
| RU2015120069A (ru) | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения | |
| JP2014502955A5 (ja) | ||
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2013515472A5 (ja) | ||
| JP2005533001A5 (ja) | ||
| JP2017113019A5 (ja) | ||
| JP2016529215A5 (ja) | ||
| HRP20140604T1 (hr) | Sredstva koja djeluju na cd138 i njihova upotreba | |
| JP2013532181A5 (ja) | ||
| JP2015529225A5 (ja) | ||
| JP2015534578A5 (ja) | ||
| JP2013517277A5 (ja) | ||
| JP2009522302A5 (ja) | ||
| JP2008538564A5 (ja) | ||
| JP2020502219A5 (ja) | ||
| JP2012034692A5 (ja) |